Malaysia should assess whether higher valency pneumococcal vaccines offer enough added protection to justify their higher cost. Experts say vaccine choice should be guided by local disease patterns, stronger surveillance, and cost-effectiveness. The post Higher Valency Pneumococcal Vaccines Need Stronger Local Evidence: Experts appeared first on CodeBlue.